Test Overview
Polymerase Chain Reaction (PCR) including Restriction Digest
Determining the specific apolipoprotein E (APOE) genotypes in patients with type III hyperlipoproteinemia.
Interpretive report provided. This test detects the Apo E2, E3, and E4 genes.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
This assay will not detect all of the mutations that cause type III hyperlipoproteinemia. Therefore, the absence of a detectable mutation does not rule out the possibility that an individual is a carrier of or affected with this disease. This assay cannot predict or rule out the development of Alzheimer disease in an individual. Rare polymorphisms exist that could lead to false-negative or false-positive results. If results obtained do not match the clinical findings, additional testing should be considered.
Test Details
6 - 10 days
- Apo E Genotyping
- Apolipoprotein E Genotyping by DNA Analysis
- Apo E2 Gene Detection
- Apo E3 Gene Detection
- Apo E4 Gene Detection
Specimen Requirements
Collect blood in a lavender top tube. Refrigerate and send intact blood in the original tube within 48 hours of collection
Extracted DNA: Additional Information: DNA must be extracted in a CLIA-certified laboratory or equivalent and must be extracted from a specimen type listed as acceptable for this test (including applicable anticoagulants). Our laboratory has experience with Chemagic, Puregene, Autopure, MagnaPure, and EZ1 extraction platforms and cannot guarantee that all extraction methods are compatible with this test. If testing fails, one repeat will be attempted, and if unsuccessful, the test will be reported as failed and a charge will be applied. If applicable, specific gene regions that were unable to be interrogated due to DNA quality will be noted in the report.
Extracted DNA: Frozen (stable 1 year)
Additional Information
Test sent to Mayo Medical Laboratories. Specimens sent for Alzheimer's risk assessment are referred to Athena Diagnostics. The Apo E4 allele has been associated with an increased risk for late onset Alzheimer's dementia.